According to figures released by Kobayashi Pharmaceutical, inquiries related to deaths associated with its red yeast rice supplement rose to 429, while the number of cases subject to detailed investigation increased to 156 and the number still under investigation rose to 1. The number of patients seen for conditions unrelated to renal issues also increased, bringing the total number of inpatients and outpatients to 3,411.
According to figures released by Kobayashi Pharmaceutical as of 4 October, death-related inquiries totaled 429, an increase of 1 from 20 September. Cases subject to detailed investigation increased to 156, comprising 1 case still under investigation, 55 completed investigations and 100 other cases.
The breakdown of death-related cases was 273 cases in which there was no evidence of consumption, 0 cases in which consumption was still being confirmed, and 156 cases subject to detailed investigation. Compared with 20 September, death-related inquiries, cases subject to detailed investigation and cases still under investigation each increased by 1.
The number of patients seen, including those with conditions unrelated to renal disease, increased to 619 inpatients and 2,792 outpatients, 3,411 in total, as of 4 October. Among patients with renal-related disease, the figures were 353 inpatients and 1,889 outpatients, 2,242 in total, unchanged from the previous figures.
Regarding the causal relationship between consumption and the deaths, Kobayashi Pharmaceutical continues to state that there are no clear cases of death caused by consumption. Although the latest figures confirm increases in death-related inquiries and cases subject to detailed investigation, the published materials do not indicate whether the increase resulted from the same case.